8-K
Exicure, Inc. (XCUR)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2024
____________________
EXICURE, INC.
(Exact name of Registrant as specified in its charter)
____________________
| Delaware | 001-39011 | 81-5333008 |
|---|---|---|
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
2430 N. Halsted St.
Chicago, IL 60614
(Address of principal executive offices)
Registrant’s telephone number, including area code: (847) 673-1700
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock, par value $0.0001 per share | XCUR | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Item 2.02 Results of Operations and Financial Condition.
On August 13, 2024, Exicure, Inc. (the “Company”) issued a press release announcing its financial and operational results for the quarter ended June 30, 2024. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 2.02 in the Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall such information be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
| Exhibit<br>No. | Description |
|---|---|
| 99.1 | Press release dated August 13, 2024 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 13, 2024 | EXICURE, INC. | |
|---|---|---|
| By: | /s/ Paul Kang | |
| Paul Kang | ||
| Chief Executive Officer |
Document
| Exhibit 99.1 |
|---|
Exicure, Inc. Reports Second Quarter 2024 Financial Results
CHICAGO, IL — August 13, 2024 — Exicure, Inc. (Nasdaq: XCUR, the "Company"), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.
Second Quarter 2024 Financial Results
Cash Position: Cash and cash equivalents were $0.5 million as of June 30, 2024, as compared to $0.8 million as of December 31, 2023. The Company believes that its cash and cash equivalents are insufficient to continue to fund operations and additional funding is needed in the very near term.
General and Administrative (G&A) Expense: General and administrative expenses were $1.2 million for the quarter ended June 30, 2024, as compared to $5.6 million for the quarter ended June 30, 2023. The decrease in G&A expense of $4.4 million for the three months ended June 30, 2024 was mostly due to higher costs in 2023 due to separation pay for executives and related stock based compensation expense, and consulting fees, partially offset by lower bonus, retention, and insurance expense.
Other Income: The Company sold samples of its clinical products for $0.6 million to a private clinical stage biopharmaceutical company.
Net Loss: The Company had a net loss of $0.6 million for the quarter ended June 30, 2024, as compared to a net loss of $5.8 million for the quarter ended June 30, 2023. The decrease in net loss of $5.2 million was primarily driven by the reduction of payroll and operating costs due to reduced operations, as well as $0.6 million of other income.
Going Concern: Management believes that the Company’s existing cash and cash equivalents is not sufficient to continue to fund operations. The Company has already engaged in significant cost reductions, so our ability to further cut costs and extend the Company’s operating runway is limited. As a result, substantial additional financing is needed in very near term to pay expenses, fund the ongoing exploration of strategic alternatives and pursue any alternatives that may be identified. The Company needs to raise capital to fund its operations. There can be no assurance that such additional financing will be available and, if available, can be obtained on acceptable terms.
About Exicure
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical fact may be deemed forward looking including, but not limited to, statements regarding: the Company’s current business plans and objectives, including the pursuit of strategic alternatives to maximize stockholder value. Words such as “plans,” “expects,” “will,” “anticipates,” “continue,” “advance,” “believes,” “target,” “may,” “intend,” “could,” and other words and terms of similar meaning and expression are intended to identify forward-looking statements, although not all forward-looking statements contain such terms. Forward-looking statements are based on management’s current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Company’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on June 6, 2024, as updated by the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information or to publicly announce the results of any revisions to any of such statements to reflect future events or developments, except as required by law.
Media Contact:
Josh Miller
847-673-1700
media@exicuretx.com
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
| June 30,<br>2024 | December 31,<br>2023 | |||
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 528 | $ | 816 |
| Other receivable | 559 | 15 | ||
| Prepaid expenses and other current assets | 992 | 1,193 | ||
| Total current assets | 2,079 | 2,024 | ||
| Property and equipment, net | 40 | 54 | ||
| Right-of-use asset | 6,126 | 6,517 | ||
| Other noncurrent assets | 2,443 | 2,985 | ||
| Total assets | $ | 10,688 | $ | 11,580 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current liabilities: | ||||
| Accounts payable | 1,585 | 1,631 | ||
| Accrued expenses and other current liabilities | 846 | 879 | ||
| Short-term debt | 1,000 | — | ||
| Total current liabilities | 3,431 | 2,510 | ||
| Lease liability, noncurrent | 5,644 | 6,039 | ||
| Total liabilities | $ | 9,075 | $ | 8,549 |
| Commitments and Contingencies (Note 12) | ||||
| Stockholders’ equity: | ||||
| Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized, no shares issued and outstanding, June 30, 2024 and December 31, 2023 | — | — | ||
| Common stock, $0.0001 par value per share; 200,000,000 shares authorized, 8,651,148 issued and outstanding, June 30, 2024; 8,650,753 issued and outstanding, December 31, 2023 | 1 | 1 | ||
| Additional paid-in capital | 192,604 | 192,593 | ||
| Accumulated deficit | (190,992) | (189,563) | ||
| Total stockholders' equity | 1,613 | 3,031 | ||
| Total liabilities and stockholders’ equity | $ | 10,688 | $ | 11,580 |
EXICURE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
| Three Months Ended<br>June 30, | Six Months Ended<br>June 30, | |||||||
|---|---|---|---|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |||||
| Revenue: | ||||||||
| Revenue | $ | — | $ | — | $ | 500 | $ | — |
| Total revenue | — | — | 500 | — | ||||
| Operating expenses: | ||||||||
| Research and development expense | — | — | — | 1,423 | ||||
| General and administrative expense | 1,235 | 5,642 | 2,571 | 8,758 | ||||
| Total operating expenses | 1,235 | 5,642 | 2,571 | 10,181 | ||||
| Operating loss | (1,235) | (5,642) | (2,071) | (10,181) | ||||
| Other income, net: | ||||||||
| Dividend income | 1 | 15 | 5 | 32 | ||||
| Interest income | 3 | 13 | 6 | 24 | ||||
| Interest expense | (6) | — | (6) | — | ||||
| Other income | 637 | — | 637 | — | ||||
| Other expense | — | (150) | — | (46) | ||||
| Total other income, net | 635 | (122) | 642 | 10 | ||||
| Net loss before provision for income taxes | (600) | (5,764) | (1,429) | (10,171) | ||||
| Provision for income taxes | — | — | — | — | ||||
| Net loss | $ | (600) | $ | (5,764) | $ | (1,429) | $ | (10,171) |
| Basic and diluted loss per common share | $ | (0.07) | $ | (0.68) | $ | (0.17) | $ | (1.38) |
| Weighted-average basic and diluted common shares outstanding | 8,651,078 | 8,432,394 | 8,650,878 | 7,366,594 |
4